Aperio Group LLC lifted its stake in Teleflex Incorporated (NYSE:TFX) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,874 shares of the medical technology company’s stock after purchasing an additional 740 shares during the period. Aperio Group LLC’s holdings in Teleflex were worth $3,958,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Marshall Wace LLP grew its holdings in Teleflex by 1,177.7% during the 2nd quarter. Marshall Wace LLP now owns 342,631 shares of the medical technology company’s stock worth $91,897,000 after acquiring an additional 315,814 shares in the last quarter. Jennison Associates LLC bought a new position in Teleflex during the 2nd quarter worth about $60,706,000. Mar Vista Investment Partners LLC bought a new position in Teleflex during the 2nd quarter worth about $37,996,000. Orbimed Advisors LLC grew its holdings in Teleflex by 62.7% during the 2nd quarter. Orbimed Advisors LLC now owns 190,400 shares of the medical technology company’s stock worth $51,067,000 after acquiring an additional 73,400 shares in the last quarter. Finally, Scout Investments Inc. grew its holdings in Teleflex by 106.9% during the 3rd quarter. Scout Investments Inc. now owns 132,023 shares of the medical technology company’s stock worth $35,130,000 after acquiring an additional 68,198 shares in the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.
Several research analysts have issued reports on TFX shares. ValuEngine upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, September 13th. Morgan Stanley dropped their target price on shares of Teleflex from $310.00 to $295.00 and set an “overweight” rating on the stock in a report on Friday, August 3rd. Needham & Company LLC upgraded shares of Teleflex from a “buy” rating to a “strong-buy” rating and increased their target price for the stock from $279.00 to $300.00 in a report on Monday, September 10th. Piper Jaffray Companies increased their target price on shares of Teleflex to $310.00 and gave the stock an “overweight” rating in a report on Friday. Finally, TheStreet cut shares of Teleflex from a “b” rating to a “c+” rating in a report on Friday, August 3rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Teleflex presently has a consensus rating of “Buy” and an average price target of $289.38.
In other Teleflex news, CFO Thomas E. Powell sold 5,200 shares of the stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $240.02, for a total transaction of $1,248,104.00. Following the completion of the sale, the chief financial officer now directly owns 15,351 shares of the company’s stock, valued at $3,684,547.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Benson Smith sold 9,331 shares of the stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $241.84, for a total transaction of $2,256,609.04. Following the sale, the director now directly owns 77,887 shares of the company’s stock, valued at $18,836,192.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 98,491 shares of company stock valued at $25,016,762. Insiders own 2.56% of the company’s stock.
TFX stock opened at $256.13 on Friday. The stock has a market cap of $11.73 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 1.80 and a beta of 1.12. Teleflex Incorporated has a one year low of $227.52 and a one year high of $288.78. The company has a quick ratio of 1.45, a current ratio of 2.21 and a debt-to-equity ratio of 0.88.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, November 1st. The medical technology company reported $2.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.11. The business had revenue of $609.70 million during the quarter, compared to analyst estimates of $609.05 million. Teleflex had a net margin of 2.81% and a return on equity of 18.17%. The company’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.12 earnings per share. Analysts predict that Teleflex Incorporated will post 9.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Thursday, November 15th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. Teleflex’s payout ratio is 16.19%.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Article: Insider Trading – What You Need to Know
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.